NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
about
Modulation of tumor necrosis factor by microbial pathogens.RIP3, a novel apoptosis-inducing kinaseCleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosisCaspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosisFunctional isoforms of IkappaB kinase alpha (IKKalpha) lacking leucine zipper and helix-loop-helix domains reveal that IKKalpha and IKKbeta have different activation requirementsStat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activationInteraction of TAFII105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genesThe apoptotic signaling pathway activated by Toll-like receptor-2Regulation of Fas (CD95)-induced apoptosis by nuclear factor-KB and tumor necrosis factor- alpha in macrophagesCD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cellsInterchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signalingNonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activationA splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivatorDaxx silencing sensitizes cells to multiple apoptotic pathwaysTWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8Hydrogen sulfide-linked sulfhydration of NF-κB mediates its antiapoptotic actionsA20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells.VIAF, a conserved inhibitor of apoptosis (IAP)-interacting factor that modulates caspase activationBreast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathwayCompetitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1Identification of an antiapoptotic protein complex at death receptorsThe USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2Pellino3 targets RIP1 and regulates the pro-apoptotic effects of TNF-αThe PI3K-PDK1 connection: more than just a road to PKBStress-induced decrease in TRAF2 stability is mediated by Siah2Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs.A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome entry site-mediated translationIncreased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAILNF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosisT-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectinIs NF-kappaB a good target for cancer therapy? Hopes and pitfallsMechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomac-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activationThe prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosisAutocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosisFailure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient miceNAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathwaysIntrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalisSafety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
P2860
Q21089629-EE4AC38F-1139-48D7-9A3F-DB52FB87F2CEQ22009930-FCBB4C70-F8C0-4204-9F9C-65CD71659AF1Q22010649-AE1E9B74-619B-43AA-91BE-C888F32BCC83Q22253249-6B2EA1B3-F5BE-4A5F-AC6F-5D7EF1EF6236Q22253369-B765A608-E3C8-4145-82C1-DA4480162EE8Q22254226-C57E31E7-DF76-4172-B6B5-D7F881FA8C51Q22254261-2CCE1C0F-55A5-4427-9960-A3B779654BC9Q22254416-6E8751C7-8CC8-4611-A437-28D93C335A43Q23910429-B760E48B-6B08-45FC-BE57-A0D75C9E99B8Q24291469-BDEFEF18-0E1A-4356-857A-F21C82AAA9D9Q24291474-E5A0EE48-3BCD-48CA-9DB3-1D4D56915753Q24292240-3DE43F6F-8D31-4CCC-AB0F-0592D05C9506Q24295232-3098EAA7-6256-46DA-8C41-4F8854B53F12Q24296344-E1C84669-08FC-4F21-A1E9-11EAC5627564Q24300508-07A23A81-6D11-462C-AF24-7CB7B4D05B33Q24301813-1635FE99-FD0F-4FD0-85FF-AA72BE616160Q24304048-90B4CE63-65FA-4C4A-ABAF-8D3AF99B37DFQ24304221-1A8AAC54-569E-42DD-9F54-0EDF94F9CC22Q24304385-1732FFB1-65A1-4F63-9B83-F0E462A8446BQ24306159-BF1C2B9E-F9F1-414B-9719-88335B423FC6Q24317322-9418E52F-B4CB-42CD-971E-51522D52418EQ24321594-277AABD4-DDF0-4A9A-BE00-14EC1B9FBD2EQ24323126-1F4AEE4E-B81E-48E8-8074-E93CF4F89737Q24338172-2A8621BF-B668-4DF8-995A-B14C22B22E9AQ24531972-9AA074B5-C978-4FEB-AA91-80ADAD5400EDQ24539054-B4436373-067F-4AB3-A954-E7E0FFD5FB2EQ24544173-90497537-E0D8-4496-AA11-85D66657DC61Q24554349-E709612A-CEB1-414A-9696-9AF5C59FCF96Q24554360-B0A6729B-7A92-442A-BF27-2B95D7D1446EQ24554454-1A170446-5D95-4E5B-AC9A-A7B10CCADC4CQ24564272-141A7405-4997-44D3-A08E-59D5C4856CF7Q24570128-A359B9C1-F829-483A-ADAD-2D2A4CC2400DQ24605861-9964C085-2451-4F1A-AE22-3731BECDFED6Q24607621-0A0AE373-E97F-44B5-9D9B-821995354FCFQ24608044-365386CB-C164-454D-A746-CB7755ACDF10Q24609324-5ED3C8E0-3A4B-480F-9AC6-82906DA01865Q24616207-20CCCA44-F1C7-4D7B-BF2C-9DFFD35AA275Q24631606-05159C40-1AA9-4784-8852-011F6914CA75Q24633584-C492F296-7025-4687-9AD9-DA90B4EB0861Q24633761-9F879470-916F-4434-BA23-28802A8C3E75
P2860
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@ast
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@en
type
label
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@ast
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@en
prefLabel
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@ast
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@en
P2093
P3181
P1433
P1476
NF-kappaB antiapoptosis: induc ...... suppress caspase-8 activation
@en
P2093
P304
P3181
P356
10.1126/SCIENCE.281.5383.1680
P407
P577
1998-09-11T00:00:00Z